Cannaflos - Gesellschaft Für Medizinisches Cannabis Mbh
Pharmaceutical Companies · Köln
Cannaflos - Gesellschaft Für Medizinisches Cannabis Mbh is a pharmaceutical company based in Köln, North Rhine-Westphalia, Germany. The company operates in the German pharmaceutical market and is regulated by the BfArM (Federal Institute for Drugs and Medical Devices).
Content in German
The detailed company information on this page is provided in the original German language. You can use your browser's built-in translation feature to view it in English.
Right-click on the page and select "Translate to English" or use the translation icon in your browser's address bar.
Cannaflos - Gesellschaft Für Medizinisches Cannabis Mbh Address & Contact
Cannaflos GmbH Overview
Cannaflos – Gesellschaft für Medizinisches Cannabis mbH is a Cologne-based pharmaceutical company specializing in the import and distribution of medical cannabis for the German pharmacy market. Cologne, North Rhine-Westphalia, is a strategically advantageous location for cannabis trade due to its importance as a pharmaceutical hub with direct access to international logistics routes. The city benefits from an excellent infrastructure, allowing Cannaflos to respond promptly to market needs and consistently offer fresh products. Proximity to educational and research institutions in the region also underscores the innovative power of this company, which adapts to the dynamically evolving demand for medical cannabis.
Field of Activity & Products
Cannaflos sources medical cannabis products from EU-GMP-certified producers and provides these to German pharmacies via authorized pharmaceutical wholesalers. The product range includes cannabis flowers and cannabis extracts in various active ingredient compositions for patients with appropriate medical prescriptions. The offered products also include specific mixtures tailored to individual complaints. These specialized formulations enable targeted treatment of conditions such as chronic pain, multiple sclerosis, as well as nausea and vomiting related to chemotherapy. A notable feature of Cannaflos is the close collaboration with medical professionals to optimally address patient needs and provide evidence-based information.
Regulation
The company holds all licenses required under the German Narcotics Act (BtMG) and is subject to supervision by the cannabis agency of the BfArM. All products distributed must meet the quality requirements of the German pharmacy and are regularly tested for purity and active ingredient content. These strict regulatory frameworks not only ensure patient safety but also the quality of the products that Cannaflos distributes. Furthermore, the company adheres to EU legislation regarding the manufacture and marketing of pharmaceuticals. Therefore, all production and processing processes are regularly audited and optimized to ensure the highest standards. This positions Cannaflos not only as a reliable provider but also as a responsible player in the industry.
Regional Importance
Cannaflos plays a central role in the regional healthcare system of North Rhine-Westphalia. By supplying numerous pharmacies in the region, the company makes a significant contribution to the care of patients who depend on medical cannabis. Additionally, Cannaflos actively participates in dialogues about medical cannabis and collaborates with health institutions and professional societies. This not only promotes understanding of medical cannabis in the public but also acceptance among doctors and health experts.
Special Features
One remarkable aspect of Cannaflos GmbH is its commitment to research. The company collaborates with scientific institutions and supports projects that address the efficacy and therapeutic possibilities of cannabis. These initiatives are designed to collect sound data and insights that can ultimately advance the medical application of cannabis. Additionally, Cannaflos places great emphasis on transparency and education: regular training for pharmacy staff as well as the provision of informational materials for patients are part of the company's strategy. This not only promotes informed use of the products but also strengthens trust in the entire industry.
More information: Pharmaceutical companies in North Rhine-Westphalia or all pharmaceutical companies in Germany on Sanoliste.
Frequently asked questions about Cannaflos - Gesellschaft Für Medizinisches Cannabis Mbh
What does Cannaflos do?
Cannaflos - company Für Medizinisches Cannabis Mbh is in the development of innovativen medicinesn tätig, um gemeinsam with Ärzten, Pharmazeuten and wissenschaftlichen Fachgesellschaften neue Therapieoptionen zu herzustellen.
More Pharmaceutical Companies in Köln
Pharmaceutical Companies in Germany
Related areas in healthcare
Pharmaceutical Companies by location
About Pharmaceutical Companies
Germany is one of the world's leading pharmaceutical nations, home to more than 1,000 pharmaceutical businesses employing approximately 130,000 people (vfa 2023). Companies operating in this sector develop, manufacture and distribute medicines across the entire value chain, from early-stage research and clinical trials through to market authorisation and commercial distribution. In Germany, every manufacturer of medicinal products must hold a manufacturing authorisation (Herstellungserlaubnis) issued under Section 13 of the AMG (Arzneimittelgesetz, Germany's Medicinal Products Act). Medicines may only be placed on the market after receiving approval from either BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte, Germany's Federal Institute for Drugs and Medical Devices, broadly comparable to the FDA in the United States or the MHRA in the United Kingdom) or the European Medicines Agency (EMA) via the centralised procedure. All manufacturing sites are subject to regular GMP (Good Manufacturing Practice) inspections carried out by the competent pharmaceutical supervisory authority of the relevant German federal state. The sector covers prescription-only medicines (Rx), non-prescription OTC products, generics, biosimilars and active pharmaceutical ingredients (APIs). This directory lists pharmaceutical manufacturers, marketers and licence holders across all German federal states with full contact details, addresses and phone numbers.
Germany's Pharmaceutical Industry
Germany is consistently ranked among the top five pharmaceutical markets worldwide, generating annual revenues exceeding EUR 50 billion and accounting for the largest share of pharmaceutical production in continental Europe. The industry is represented by two major associations: vfa (Verband Forschender Arzneimittelhersteller), which represents research-based companies, and BAH (Bundesverband der Arzneimittel-Hersteller), which represents the broader manufacturer base including OTC and self-medication products. German pharmaceutical companies cover the full spectrum from global innovator corporations and mid-sized specialty manufacturers to generic producers and biotech firms. The country is a world leader in active pharmaceutical ingredient (API) production, biologics manufacturing and pharmaceutical chemistry. Key therapeutic areas of strength include oncology, cardiovascular medicine, immunology, neuroscience and rare diseases. Germany also serves as a significant export hub, with pharmaceutical products among the country's leading export categories. The sector benefits from a highly skilled workforce, world-class university research institutions and a dense network of research hospitals (Universitätsklinika) that facilitate clinical trial activity.
Regulatory Framework: BfArM, EMA and the AMG
The legal foundation for pharmaceutical activity in Germany is the Arzneimittelgesetz (AMG, German Medicinal Products Act), which regulates the authorisation, manufacture, import, distribution, labelling and pharmacovigilance of medicinal products. For English-speaking readers unfamiliar with the German regulatory landscape: BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is the national competent authority responsible for approving medicines marketed only in Germany, supervising narcotics, and maintaining the pharmacovigilance database. BfArM is a higher federal authority (Bundesoberbehörde) subordinate to the Federal Ministry of Health (Bundesministerium für Gesundheit). For medicines approved via the centralised EU procedure, the European Medicines Agency (EMA) grants a single marketing authorisation valid in all 27 EU member states. Germany is also home to the Paul-Ehrlich-Institut (PEI), a second federal authority that specifically handles biological medicines including vaccines, blood products and gene therapy products. Manufacturing sites are inspected by state-level pharmaceutical supervisory authorities (Landesbehörden) to verify GMP compliance, with findings entered into the EudraGMDP database operated by the EMA.
Regional Pharmaceutical Clusters in Germany
Germany's pharmaceutical industry is geographically distributed across several major regional clusters. The Rhine-Main area around Frankfurt and Leverkusen in North Rhine-Westphalia is home to some of Germany's largest pharmaceutical sites, including facilities belonging to global corporations with long histories in German chemistry and pharmaceuticals. Bavaria (particularly Munich, Penzberg and Marburg) is a second major hub, especially strong in biotechnology and biologics production. Baden-Württemberg, including cities such as Mannheim, Heidelberg and Biberach an der Riss, is home to several significant research-based manufacturers. Hamburg and the northern German region have a cluster of specialty and generic manufacturers. Berlin has a growing biotech scene connected to its research universities and the Charité hospital. Hesse is notable for its proximity to Frankfurt's logistics infrastructure and several major API manufacturers. Smaller but significant clusters exist in Saxony (Leipzig, Dresden) and Lower Saxony, benefiting from proximity to university research centres and historically established chemical industry sites.
Drug Classes and Product Segments
German pharmaceutical companies cover all major drug classes. Prescription (Rx) products account for the largest share of revenue; generics manufacturers such as Stada, ratiopharm (Teva) and Hexal produce chemically equivalent alternatives after patent expiry, significantly reducing costs for the healthcare system. Biologics and biosimilars are gaining ground rapidly: monoclonal antibodies, insulin analogues and recombinant growth factors require specialised biotech manufacturing facilities. OTC products (over-the-counter), i.e. medicines available without a prescription, represent a multi-billion-euro market served by companies such as Bayer Consumer Health, Stada and Klosterfrau. Homeopathic preparations, herbal medicines and dietary supplements form further regulated segments. Digitalisation is increasingly shaping the sector: Digital Health Applications (DiGA) have been reimbursable since 2020, and AI-assisted drug development is significantly shortening time-to-market.
What does a pharmaceutical company do?
Pharmaceutical companies develop, produce and distribute medicines. They cover the entire value chain from research and clinical trials through to market launch and distribution. In Germany, they are supervised by BfArM (the Federal Institute for Drugs and Medical Devices, comparable to the FDA or MHRA).
How are pharmaceutical companies regulated in Germany?
Pharmaceutical companies in Germany must hold a manufacturing authorisation under Section 13 of the AMG (German Medicinal Products Act). All authorised medicines require approval from either BfArM or the European Medicines Agency (EMA). Regular GMP (Good Manufacturing Practice) inspections ensure quality standards are maintained.
Where can I find contact details for pharmaceutical companies in Germany?
Industry associations such as vfa (Association of Research-Based Pharmaceutical Companies) and BPI (Federal Association of the German Pharmaceutical Industry) maintain member directories. Many companies also list their key contacts directly on their websites. Sanoliste provides a searchable directory of pharmaceutical companies in Germany sorted by federal state and city.
How many pharmaceutical companies are there in Germany?
Germany is home to more than 1,000 pharmaceutical companies employing approximately 130,000 people, according to vfa (the Association of Research-Based Pharmaceutical Companies) 2023 data. The sector includes multinational corporations, mid-sized specialty firms, generic manufacturers and biotech startups.
What is BfArM and what does it regulate?
BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is Germany's Federal Institute for Drugs and Medical Devices. It is a higher federal authority within the portfolio of the Federal Ministry of Health and is responsible for approving medicines for the German market, monitoring drug safety (pharmacovigilance), regulating narcotics and controlled substances, and overseeing medical devices in Germany. It is broadly comparable to the FDA in the United States or the MHRA in the United Kingdom.
What is the difference between BfArM approval and EMA approval?
Medicines in Germany can be approved through two main routes. BfArM grants national marketing authorisations valid in Germany, or decentralised and mutual recognition procedure approvals valid in multiple EU states. The EMA (European Medicines Agency) grants centralised marketing authorisations valid in all 27 EU member states simultaneously, typically used for innovative biologic medicines, oncology drugs and products for rare diseases.
What does GMP mean in the context of German pharmaceutical manufacturing?
GMP stands for Good Manufacturing Practice. In Germany and the EU, GMP compliance is a legal requirement for all pharmaceutical manufacturers under the AMG and the EU GMP Guidelines (EudraLex Volume 4). GMP covers all aspects of production including premises, equipment, personnel qualification, process validation, documentation and quality control. Compliance is verified by regular inspections from the competent state pharmaceutical supervisory authority.